Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4576760
Max Phase: Preclinical
Molecular Formula: C17H15ClN6
Molecular Weight: 338.80
Molecule Type: Unknown
Associated Items:
ID: ALA4576760
Max Phase: Preclinical
Molecular Formula: C17H15ClN6
Molecular Weight: 338.80
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Clc1cc(NCC2CC2)c2ncc(-c3ccc4[nH]cnc4c3)n2n1
Standard InChI: InChI=1S/C17H15ClN6/c18-16-6-14(19-7-10-1-2-10)17-20-8-15(24(17)23-16)11-3-4-12-13(5-11)22-9-21-12/h3-6,8-10,19H,1-2,7H2,(H,21,22)
Standard InChI Key: BCZVWAYFOJYNBL-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 338.80 | Molecular Weight (Monoisotopic): 338.1047 | AlogP: 3.75 | #Rotatable Bonds: 4 |
Polar Surface Area: 70.90 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.04 | CX Basic pKa: 5.61 | CX LogP: 2.58 | CX LogD: 2.58 |
Aromatic Rings: 4 | Heavy Atoms: 24 | QED Weighted: 0.59 | Np Likeness Score: -1.36 |
1. Colombano G, Caldwell JJ, Matthews TP, Bhatia C, Joshi A, McHardy T, Mok NY, Newbatt Y, Pickard L, Strover J, Hedayat S, Walton MI, Myers SM, Jones AM, Saville H, McAndrew C, Burke R, Eccles SA, Davies FE, Bayliss R, Collins I.. (2019) Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease., 62 (5): [PMID:30779566] [10.1021/acs.jmedchem.8b01721] |
Source(1):